Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
